Tag: Oxford Pharmascience

November 29, 2017 Off

Oxford Pharmascience can develop OXPzero Ibuprofen for approval in the US without Phase III trials

Oxford Pharmascience has gotten pre-IND scientific advice from the US regulatory drugs and foods authority about the development programme requirements likely…

March 10, 2017 Off

Oxfor Pharmascience reduces loss year over year with less clinical trials

By Dino Mustafić

Oxford Pharmascience Group has posted full year loss before tax £1.9m, compared to 2015’s £3.9m, citing lower number of clinical…